Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01181908 | Alcohol Interaction Study | PHASE1 | COMPLETED | 21 | — | — | Nov 11, 2009 | Dec 30, 2009 | Jun 27, 2017 | 1 | Netherlands |
| Arm | Type | Description |
|---|---|---|
| GSK1144814 | EXPERIMENTAL | Subjects will receive either GSK1144814 or placebo at each treatment arm. |
| placebo | PLACEBO_COMPARATOR | Subjects will receive either GSK1144814 or placebo at each treatment arm. |
| Name | Type | Description |
|---|---|---|
| single dose | DRUG | Subjects will receive a single dose of GSK1144814 or placebo. |
Inclusion Criteria: * Healthy male and female * Body weight 50 kg or higher and BMI within the range 19 - 29.9 kg/m2 * Willing to use appropriate contraception methods Exclusion Criteria: * Positive HIV, Hepatitis B surface antigen or Hepatitis C antibody result * Any serious medical disorder or ...